Welcome to our dedicated page for Disc Medicine SEC filings (Ticker: IRON), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Disc Medicine filings document the regulatory and financial record of a clinical-stage biopharmaceutical company developing hematologic disease therapies. Its Form 8-K disclosures cover quarterly and annual financial results, corporate updates, clinical-program materials for bitopertin, DISC-0974 and DISC-3405, and FDA communications related to the bitopertin New Drug Application for erythropoietic protoporphyria.
The filing record also includes proxy materials covering board matters, executive compensation and shareholder voting items. Material-event reports describe Regulation FD presentations, operating runway disclosures, restructuring actions following regulatory developments, and risk-related statements around clinical trials, regulatory pathways, research spending and capital resources.
Disc Medicine, Inc. is implementing a restructuring plan after receiving a complete response letter from the FDA on February 13, 2026 regarding its New Drug Application for bitopertin for erythropoietic protoporphyria and X-linked protoporphyria. The board approved the plan on February 26, 2026.
The company is reducing its workforce by approximately 20%, mainly in commercial and certain supporting functions, and expects to complete the restructuring in the second quarter of 2026. Disc Medicine expects to incur about $2.0 million of charges, primarily severance costs, recorded mainly in the first quarter of 2026, though actual costs may differ and additional expenses are possible.
Disc Medicine provides an update on its clinical-stage pipeline for serious hematologic diseases and key regulatory developments. The company remains pre-revenue, focused on red blood cell biology via heme biosynthesis and iron homeostasis pathways.
Lead candidate bitopertin targets erythropoietic porphyrias, including EPP and XLP. Phase 2 trials (BEACON and AURORA) significantly lowered toxic PPIX levels and showed improved light tolerance and quality of life, with generally good tolerability. However, the FDA issued a complete response letter in February 2026, finding existing data insufficient to support accelerated approval. Disc is running the Phase 3 APOLLO trial, with topline data expected in the fourth quarter of 2026, to support a potential traditional approval.
In iron homeostasis, DISC-0974 (anti-HJV) is in Phase 2 for anemia of myelofibrosis, where early data showed large hepcidin reductions, improved iron markers, higher hemoglobin and meaningful transfusion reductions. DISC-3405 (anti-TMPRSS6) is in Phase 2 for polycythemia vera and Phase 1b for sickle cell disease, with Phase 1 data demonstrating increased hepcidin and reduced serum iron. Preclinical antibody DISC-0998 targets anemia linked to inflammatory diseases. As of June 30, 2025, Disc’s non-affiliate equity value was about $1.4 billion, with 38,160,065 common shares outstanding as of February 19, 2026.
Disc Medicine reported a larger full-year 2025 net loss of $212.2 million, or $6.01 per share, as it increased investment in its hematology pipeline. Research and development expenses rose to $170.6 million and selling, general and administrative costs to $65.4 million, reflecting advancing trials and commercialization preparations.
Cash, cash equivalents, and marketable securities reached $791.2 million as of December 31, 2025, boosted by $454.4 million of net proceeds from 2025 equity offerings, supporting a cash runway into 2029. The company received an FDA Complete Response Letter for bitopertin in EPP but is pursuing a traditional approval path, with Phase 3 APOLLO topline data expected in Q4 2026.
IRON — Form 144: reported insider sale activity. The filing lists Restricted Stock Units dated 02/15/2026 with a quantity of 7010 described under "Securities To Be Sold." It also records 10b5-1 sales for JEAN FRANCHI of Common stock on 02/18/2026 showing 7,081 shares and $463,572.54.
Disc Medicine, Inc. Chief Financial Officer Jean M. Franchi reported open-market sales of a total of 11,156 shares of common stock on February 17–18, 2026. The transactions were executed at weighted average prices of $62.8600, $65.0097, and $65.8889 per share, with footnotes noting sale price ranges between $64.47 and $66.38.
According to the disclosure, one of these transactions was a "sell to cover" sale used to satisfy tax withholding obligations related to previously vested restricted stock units, and did not represent a discretionary trade. All transactions were carried out under a pre-arranged Rule 10b5-1 trading plan adopted on September 25, 2025. After these sales, Franchi directly owned 71,343 shares of Disc Medicine common stock.
Disc Medicine, Inc. Chief Legal Officer Rahul Khara reported an open-market sale of 2,853 shares of common stock at an average price of $62.86 per share on February 17, 2026. According to the filing, this was a mandatory “sell to cover” transaction to satisfy tax withholding on vesting restricted stock units, not a discretionary sale. After this transaction, Khara directly owned 52,173 shares of Disc Medicine common stock.
Disc Medicine, Inc. Chief Commercial Officer Pamela Stephenson reported an open-market sale of 5,531 shares of common stock at $62.86 per share. According to the filing, the sale was solely to cover tax withholding on vesting restricted stock units. She now holds 80,998 shares directly.
Disc Medicine, Inc. Chief Medical Officer William Jacob Savage reported an open-market sale of 3,256 shares of common stock at $62.86 per share. According to the footnote, this was a non-discretionary “sell to cover” transaction to satisfy tax withholding obligations from vesting restricted stock units. After the sale, he directly owned 92,589 shares.
Disc Medicine, Inc. Chief Operating Officer Yu Jonathan Yen-Wen reported an open-market sale of 3,231 shares of common stock at $62.86 per share. After the transaction, he directly owns 54,324 shares. According to the footnote, the sale was solely to cover tax withholding on vesting restricted stock units and was not a discretionary trade.